Despite the strong revenue performance, the company's first-quarter financial results revealed a widening loss to $1.26 per share, as reported by Zacks. This represents a larger loss compared to the $1.22 per share recorded in the same quarter last year. This trend indicates that while Axsome Therapeutics is experiencing rapid sales growth, its operational expenses are also on the rise, impacting its overall earnings per share. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a leading biopharmaceutical company d ...